LIXT vs. KA, ENVB, ADIL, FWBI, LIPO, XBIO, HOTH, PCSA, YMTX, and GNPX
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Kineta (KA), Enveric Biosciences (ENVB), Adial Pharmaceuticals (ADIL), First Wave BioPharma (FWBI), Lipella Pharmaceuticals (LIPO), Xenetic Biosciences (XBIO), Hoth Therapeutics (HOTH), Processa Pharmaceuticals (PCSA), Yumanity Therapeutics (YMTX), and Genprex (GNPX). These companies are all part of the "pharmaceutical preparations" industry.
Lixte Biotechnology (NASDAQ:LIXT) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Kineta received 3 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Lixte Biotechnology has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Comparatively, Kineta has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Lixte Biotechnology has higher earnings, but lower revenue than Kineta. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Kineta, indicating that it is currently the more affordable of the two stocks.
Kineta has a consensus price target of $8.00, suggesting a potential upside of 1,669.91%. Given Kineta's higher probable upside, analysts clearly believe Kineta is more favorable than Lixte Biotechnology.
5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 30.3% of Kineta shares are owned by institutional investors. 15.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 29.8% of Kineta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Kineta's return on equity of -1,044.95% beat Lixte Biotechnology's return on equity.
In the previous week, Kineta had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Kineta and 1 mentions for Lixte Biotechnology. Kineta's average media sentiment score of 0.13 beat Lixte Biotechnology's score of 0.00 indicating that Kineta is being referred to more favorably in the news media.
Summary
Kineta beats Lixte Biotechnology on 12 of the 14 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
